Rare disease drug innovation: Amicus CEO

Thursday, 11 Aug 2016 | 6:41 AM ET

John Crowley, Amicus Therapeutics CEO, discusses the development of "orphan drugs" for patients with rare diseases. What I know personally and professionally is if we make great medicines, we'll not only change people lives, we'll build great businesses, says Crowley.